Repeat revascularization after acute coronary syndrome: risk factors and potential targets for therapeutic intervention
https://doi.org/10.24884/1609-2201-2024-103-1-57-61
Abstract
Acute coronary syndrome (ACS) is a life-threatening condition, for the treatment of which modern methods of myocardial revascularization are used, but in the long-term follow-up period, coronary artery restenosis often occurs, which requires re-intervention. There are many factors that influence the risk of developing long-term complications. Moreover, most of them, such as age, heredity, anatomical features of damage to the coronary arteries, are non-modifiable. At the same time, there are a number of indicators that influence the likelihood of developing restenosis, which can become a potential target for therapeutic intervention. The search for predictors of lumen loss in stented arteries is an urgent problem.
About the Authors
I. S. Trusov
Pavlov University
Russian Federation
Russian Federation
Trusov Ivan S., PhD, Associate Professor, Department of Faculty Therapy with Endocrinology and Cardiology with Clinic
6-8, L’va Tolstogo str., Saint Petersburg, 197022,
E. M. Nifontov
Pavlov University
Russian Federation
Russian Federation
Nifontov Evgeny M., MD, Professor, Professor of the Department of Faculty Therapy with a Course of Endocrinology and Cardiology with Clinic,
6-8, L’va Tolstogo str., Saint Petersburg, 197022,
References
1. Boytsov S.A., Shalnova S.A., Deev A.D. Cardiovascular mortality in the Russian Federation and possible mechanisms of its changes. S.S. Korsakov’s Journal of Neurology and Psychiatry. 2018;118(8):98– 103. (In Russ.). DOI: 10.17116/jnevro201811808198.
2. Bojcov S.A. et al. What is changing in the treatment of acute coronary syndrome in the russian federation? Rational Pharmacotherapy in Cardiology. 2022;18(6):703–709. (In Russ.). DOI:10.20996/1819-6446-2022-12-14.
3. Kashalap V.V., Zavyrylina I.N., Barbarash O.L. Endovascular revascularization for ST-elevation acute coronary syndrome in Russia: problems and prospects for the further development. Creative Cardiology. 2015;(3):5–15. (In Russ.). DOI: 10.15275/kreatkard.2015.03.01.
4. Shumakov D.V., Shekhyan G.G., Zybin D.I. et al. Late complications of percutaneous coronary interventions. RMJ. 2020; 28(10):25–28. (In Russ.).
5. Torrado J., Buckley L., Durán A. et al. Restenosis, stent thrombosis, and bleeding complications: navigating between Scylla and Charybdis. J Am Coll Cardiol. 2018;71(15):1676–1695. DOI: 10.1016/j.jacc.2018.02.023.
6. Gori T., Polimeni A., Indolfi C. et al. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol. 2018;16(4):243–256. DOI: 10.1038/s41569-018-0118-5.
7. Gallo G., Pierelli G., Forte M. et al. Role of oxidative stress in the process of vascular remodeling following coronary revascularization. Int J Cardiol. 2018;268:27–33. DOI: 10.1016/j.ijcard.2018.05.046.
8. Patel V.N., Angbohang A., Zeng L. In-stent restenosis: is low shear stress to blame? J Cardiol Clin Res. 2017;5:1106–1111.
9. Zhou J., Chen H. A real world analysis of the angiographic patterns of in-stent restenosis and clinical outcome of second drug-eluting stent implantation. Int J Clin Exp Med. 2017;10(7):11220–11225.
10. Singh A.D., Singal A.K., Mian A. et al. Recurrent drug-eluting stent in-stent restenosis: a state-of-the-art review of pathophysiology, diagnosis, and management. Cardiovascular Revascularization Medicine. 2020;9(21):1157–1163. DOI: 10.1016/j.carrev.2020.01.005.
11. Maleknia M., Ansari N., Haybar H. et al. Inflammatory growth factors and in-stent restenosis: effect of cytokines and growth factors. SN Comprehensive Clinical Medicine. 2020;2:397–407. DOI: 10.1007/s42399-020-00240-0.
12. Pepe M., Napoli G., Carulli E. et al. Autoimmune diseases in patients undergoing percutaneous coronary intervention: A risk factor for in-stent restenosis? Atherosclerosis. 2021;333:24–31. DOI: 10.1016/j.atherosclerosis.2021.08.007.
13. Cheng G., Chang F.J., Wang Y. et al. Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: a clinical trial based on 1-year follow-up. Medical science monitor: international medical journal of experimental and clinical research. 2019;25:240–247. DOI: 10.12659/msm.908692.
14. Paramasivam G., Devasia T., Jayaram A. et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. Anatolian Journal of Cardiology/Anadolu Kardiyoloji Dergisi. 2020;23(1):28–34. DOI: 10.14744/anatoljcardiol.2019.72916.
15. Osipova E.S., Veselovskaya N.G., Chumakova G.A., Elykomov V.A. Risk factors of coronary arteries restenosis after stenting in postmenopausal women with obesity. Russian Journal of Cardiology. 2018;23(5):34–39. (In Russ.). DOI: 10.15829/1560-4071-2018-5-34-39.
16. Wilson S., Mone P., Kansakar U. et al. Diabetes and restenosis. Cardiovascular Diabetology. 2022;21(1):23. DOI: 10.1186/s12933-022-01460-5.
17. Afanasiev S.A., Garganeeva A.A., Kuzheleva E.A. et al. The impact of type 2 diabetes mellitus on long-term prognosis in patients of different ages with myocardial infarction. Journal of diabetes research. 2018;2018:1780683. DOI: 10.1155/2018/1780683.
18. Trusov I.S., Nifontov E.M., Birjukov A.V., Bazunov A.K. Factors influencing the outcomes of coronary artery stenting with everolimus-eluting stents in acute coronary syndromes without ST segment elevation. Regional blood circulation and microcirculation. 2021;20(1):62–70. (In Russ.). DOI: 10.24884/1682-6655-2021-20-1-62-70.
19. Collet J.P., Thiele H., Barbato E. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Russian Journal of Cardiology. 2021;26(3):4418. DOI:10.15829/1560-4071-2021-4418.
20. Gurevich V.S., Koziolova N.A., Ezhov M.V. et al. Unresolved problems of dyslipidemia and residual cardiovascular risk. Atherosclerosis and Dyslipidemia. 2022;1(46):31–38. (In Russ.). DOI: 10.34687/2219-8202.JAD.2022.01.0003.
21. 2023 ESC Guidelines for the management of coronary syndromes. European Heart Journal: Acute Cardiovascular Care. 2023;00:1–107. DOI: 10.1093/ehjacc/zuad107.
22. Ezhov M.V., Kukharchuk V.V., Sergienko I.V. et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):250–297. (In Russ.). DOI: 10.15829/1560-4071-2023-5471.
23. Volkova A.R., Dora S.V., Berkovich O.A. et al. Subclinical hypothyroidism-a cardiovascular risk factor. Therapy. 2016;6(10):23– 28. (In Russ.). 24. Wang P., Xu T.Y., Guan Y.F. et al. Vascular smooth muscle cell apoptosis is an early trigger for hypothyroid atherosclerosis. Cardiovascular research. 2014;102(3):448–459. DOI: 10.1093/cvr/cvu056.
24. Jabbar A., Ingoe L., Thomas H. et al. Prevalence, predictors and outcomes of thyroid dysfunction in patients with acute myocardial infarction: the ThyrAMI-1 study. J Endocrinol Invest. 2021;44(6):1209–1218. DOI: 10.1007/s40618-020-01408-0.
25. Cao Q., Jiao Y., Yu T., Sun Z. Association between mild thyroid dysfunction and clinical outcome in acute coronary syndrome undergoing percutaneous coronary intervention. Cardiol J. 2020;27(3):262–271. DOI: 10.5603/cj.a2018.0097.
26. Nifontov E.M., Trusov I.S., Hachikjan T.T. et al. The influence of thyroid status on long-term complications after stenting in patients with acute coronary syndrome without ST-segment elevation. Translational Medicine. 2023;10(6):484–494. (In Russ.). DOI: 10.18705/23114495-2023-10-6-484-494.
Review
For citations:
Trusov I.S., Nifontov E.M. Repeat revascularization after acute coronary syndrome: risk factors and potential targets for therapeutic intervention. New St. Petersburg Medical Records. 2024;(1):57-61. (In Russ.) https://doi.org/10.24884/1609-2201-2024-103-1-57-61
Views:
55
Email this article 